Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 15, 2016 08:00 ET | Source: Chinook Therapeutics, Inc.

Aduro Biotech to Host Conference Call

BERKELEY, Calif., May 15, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that it will hold a conference call tomorrow, May 16, 2016, at 6:00 am Pacific Time. To...
May 12, 2016 16:00 ET | Source: Chinook Therapeutics, Inc.

Aduro Biotech Announces First Patient Dosed in Phase 1 Study of ADU-S100 for the Treatment of Cutaneously Accessible Tumors

BERKELEY, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the first patient has been dosed in a Phase 1 trial for ADU-S100 (also known as MIW815), a...
May 11, 2016 08:00 ET | Source: Chinook Therapeutics, Inc.

Aduro Biotech Announces Management Promotions

BERKELEY, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the promotion of Dirk Brockstedt, Ph.D., to executive vice president, research and development;...
May 02, 2016 16:00 ET | Source: Chinook Therapeutics, Inc.

Aduro Biotech Announces First Quarter 2016 Financial Results

BERKELEY, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the first quarter 2016. For the three months ended March 31, 2016, net...
April 28, 2016 09:00 ET | Source: Chinook Therapeutics, Inc.

Aduro Biotech Announces Key Preclinical Data Published Highlighting New Approach to Treat Multiple Myeloma

BERKELEY, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the publication of a pivotal paper elucidating the roles of B cell maturation antigen (BCMA)...
April 27, 2016 08:00 ET | Source: Chinook Therapeutics, Inc.

Aduro Biotech to Present at Two Upcoming Investor Conferences

BERKELEY, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present...
April 11, 2016 08:00 ET | Source: Chinook Therapeutics, Inc.

Aduro Biotech Chief Scientific Officer to Highlight the Potential of STING Activation in Cancer Immunotherapy in a Major Symposium at the 2016 American Association for Cancer Research Annual Meeting

BERKELEY, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), today announced that the company’s chief scientific officer, Thomas W. Dubensky, Jr., Ph.D., will be a...
March 28, 2016 08:00 ET | Source: Chinook Therapeutics, Inc.

Aduro Biotech and UC Berkeley Launch Industry-Leading Immunotherapeutics and Vaccine Research Initiative

Collaboration to Accelerate Breakthroughs in the Treatment and Prevention of Cancer, Infectious and Autoimmune Diseases BERKELEY, Calif., March 28, 2016 (GLOBE NEWSWIRE) -- The University of...
March 24, 2016 08:00 ET | Source: Chinook Therapeutics, Inc.

Aduro Biotech Announces First Patient Dosed in Combination Clinical Trial of CRS-207 and Epacadostat to Treat Ovarian Cancer

BERKELEY, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the first patient has been dosed in SEASCAPE, the Phase 1/2 clinical study designed to...
March 08, 2016 16:05 ET | Source: Chinook Therapeutics, Inc.

Aduro Biotech Announces Fourth Quarter and Full Year 2015 Financial Results

BERKELEY, Calif., March 08, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the year ended December 31, 2015. Net loss was $39.2 million for...